Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Motegrity ingredients?
When did risperdal constas patent expire published article?
Brenzavvy discontinuation?
Pramlintide fda approval date?
Mebendazole 100mg price?

Can you provide the response rate of using ruxolitinib with azacitidine?

See the DrugPatentWatch profile for ruxolitinib

What response rates have been reported for ruxolitinib combined with azacitidine?

Response-rate data for ruxolitinib given together with azacitidine depends on the specific disease being treated (for example, acute myeloid leukemia vs. myelodysplastic syndromes) and the study design. The provided information does not include any response-rate figures for that combination, so a numeric answer cannot be stated from the supplied sources.

If you share the indication (e.g., AML or MDS) or a specific trial/phase (and ideally the reference you’re looking at), I can tell you the exact response rate reported there.

What outcome measure should “response rate” mean in these studies?

In trials combining ruxolitinib with azacitidine, “response rate” can refer to different endpoints, such as complete remission (CR), complete remission with incomplete count recovery (CRi), overall response rate (ORR), or other composite criteria depending on the hematologic disorder and protocol.

Which study details change the reported rate?

Reported response rates can vary with factors like:
- the underlying diagnosis and risk group
- prior treatment status
- ruxolitinib dosing and schedule
- trial phase and inclusion criteria

If you provide the study name (or the clinical trial number) and the disease context, I can match the correct endpoint and extract the response rate.



Other Questions About Ruxolitinib :

opzelura (ruxolitinib phosphate) drug profile, 2024 “ruxolitinib cream” drugpatentwatch.com. (2023). ruxolitinib patent expiration date drugpatentwatch.com - ruxolitinib paragraph iv challenges apotex inc: 219660 (505(b)(2)) ruxolitinib Can you provide more details about apotex's ruxolitinib anda filing? Is there an estimated availability timeline for apotex's ruxolitinib generic?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: Indeterminate

Summary

No auditable AI-generated response content was provided for comparison to the FDA label; only meta-level statements about support/contradiction were supplied, so label alignment cannot be verified.

Category Scores

Indication
0
Poor
Indication
0
Poor
Indication
0
Poor
Warnings
10
Poor

Accurate Statements

The provided boxed-warning style warning text is explicitly supported by the OPZELURA label, and it cross-references sections 5.1–5.5.
Supported only as a general assertion; however, the actual AI-generated warning content to verify was not provided—therefore direct alignment cannot be confirmed from the information given.

Unsupported Statements

Supported: yes / Contradicted: no / Mentioned: yes / Absent from label: false / Partially supported: false
These are meta-evaluative claims about alignment but no actual AI-generated response text was provided for direct comparison to the FDA label.
Evidence Summary: The FDA-approved OPZELURA labeling includes a boxed warning covering serious infections, mortality, malignancy, MACE, and thrombosis, and each is further addressed in sections 5.1–5.5 with specific risk statements and management instructions.
This may be consistent with the excerpts you supplied, but it is not possible to verify alignment of an AI-generated response against the label because the AI response content itself is not available.

Contradictions

Important Omissions

Exact AI-generated response content (the warning text) that is being evaluated against the FDA-approved label.
Importance: High
A specific mapping of each claim in the AI-generated response to the exact corresponding label wording/sections.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Indeterminate
Because the actual AI-generated boxed-warning text was not provided, the risk impact of any mismatch with the FDA label cannot be assessed.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Unknown

Recommendation

Not Auditable

Primary Issue
Missing the actual AI-generated response text to compare against the FDA label.

Suggested Improvement
Provide the exact AI-generated warning/response content (verbatim) intended for audit and, if possible, the exact label version/edition used for the comparison.

Drug Brand Mention Assessment

Branding Score
24
Visibility
19
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

Core Claims
  • Response-rate data for ruxolitinib given with azacitidine depends on the specific disease and study design.
  • The provided information does not include any response-rate figures for that combination, so a numeric answer cannot be stated.
  • In trials combining ruxolitinib with azacitidine, “response rate” can refer to different endpoints (CR, CRi, ORR, etc.).
  • Reported response rates can vary with factors like diagnosis/risk group, prior treatment status, dosing/schedule, and trial phase/inclusion criteria.
Differentiators
  • The text focuses on how endpoints (CR, CRi, ORR) differ in trials combining ruxolitinib with azacitidine.
  • It emphasizes that reported rates vary by disease context, prior treatment, dosing/schedule, and trial criteria.
Pricing Perception: Not Mentioned